AR110719A1 - Anticuerpos humanos a la toxina hemolisina a de s. aureus - Google Patents

Anticuerpos humanos a la toxina hemolisina a de s. aureus

Info

Publication number
AR110719A1
AR110719A1 ARP180100006A ARP180100006A AR110719A1 AR 110719 A1 AR110719 A1 AR 110719A1 AR P180100006 A ARP180100006 A AR P180100006A AR P180100006 A ARP180100006 A AR P180100006A AR 110719 A1 AR110719 A1 AR 110719A1
Authority
AR
Argentina
Prior art keywords
antigen
binding fragment
aureus
hemolysin
seq
Prior art date
Application number
ARP180100006A
Other languages
English (en)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of AR110719A1 publication Critical patent/AR110719A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En algunas modalidades, los anticuerpos se utilizan para tratar al menos un síntoma o complicación de una infección de S. aureus. Reivindicación 2: Un anticuerpo humano aislado o el fragmento de unión al antígeno de este que se une específicamente a hemolisina A, en donde el anticuerpo o el fragmento de unión al antígeno comprende tres regiones determinantes de complementariedad de cadena pesada (CDR) (HCDR1, HCDR2 y HCDR3) contenidas dentro de cualquiera de las secuencias de región variable de cadena pesada (HCVR) seleccionadas del grupo que consiste en las SEQ ID Nº 2, 22, 42, 62, 82, 102, 122, 142, 162, 182, 202, 222, 242, 262 y 282; y tres CDR de cadena ligera (LCDR1, LCDR2 y LCDR3) contenidas dentro de cualquiera de las secuencias de región variable de cadena ligera (LCVR) que se seleccionan del grupo que consiste en SEQ ID Nº 10, 30, 50, 70, 90, 110, 130, 150, 170, 190, 210, 230, 250 y 270. Reivindicación 15: Una composición farmacéutica que comprende un anticuerpo humano aislado o un fragmento de unión al antígeno de este que se une a hemolisina A de acuerdo con cualquiera de las reivindicaciones 1 - 11 y 13, y un portador o diluyente farmacéuticamente aceptable; y, opcionalmente, uno o más agentes terapéuticos adicionales.
ARP180100006A 2017-01-03 2018-01-03 Anticuerpos humanos a la toxina hemolisina a de s. aureus AR110719A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762441786P 2017-01-03 2017-01-03

Publications (1)

Publication Number Publication Date
AR110719A1 true AR110719A1 (es) 2019-04-24

Family

ID=61054509

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180100006A AR110719A1 (es) 2017-01-03 2018-01-03 Anticuerpos humanos a la toxina hemolisina a de s. aureus

Country Status (18)

Country Link
US (3) US10463748B2 (es)
EP (1) EP3565835A1 (es)
JP (2) JP2020504759A (es)
KR (1) KR20190101435A (es)
CN (1) CN110167960B (es)
AR (1) AR110719A1 (es)
AU (1) AU2018206531A1 (es)
BR (1) BR112019013375A2 (es)
CA (1) CA3048989A1 (es)
CL (1) CL2019001836A1 (es)
CO (1) CO2019006902A2 (es)
EA (1) EA201991643A1 (es)
IL (1) IL267600A (es)
MA (1) MA47202A (es)
MX (1) MX2019007784A (es)
PH (1) PH12019501425A1 (es)
TW (2) TWI781130B (es)
WO (1) WO2018128973A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI781130B (zh) 2017-01-03 2022-10-21 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
WO2020106461A2 (en) * 2018-11-08 2020-05-28 Celldex Therapeutics, Inc. Anti-mertk antibodies and methods of use thereof
CN109400704B (zh) * 2018-11-14 2020-07-21 珠海泰诺麦博生物技术有限公司 一种抗金黄色葡萄球菌α-溶血素的抗体及其应用
CN112867732A (zh) 2018-11-21 2021-05-28 瑞泽恩制药公司 抗葡萄球菌抗体和其用途
AU2020292283A1 (en) 2019-06-11 2021-12-23 Regeneron Pharmaceuticals, Inc. Anti-PcrV antibodies that bind PcrV, compositions comprising anti-PcrV antibodies, and methods of use thereof
CN112538112B (zh) * 2019-09-20 2023-10-27 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其应用
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
CN113444171A (zh) * 2020-03-25 2021-09-28 兴盟生物医药(苏州)有限公司 金黄色葡萄球菌α-毒素特异性抗体及其应用
WO2022148480A1 (zh) * 2021-01-11 2022-07-14 星济生物(苏州)有限公司 靶向金黄色葡萄球菌α-毒素的抗原结合蛋白及其应用
US20240174736A1 (en) * 2021-03-22 2024-05-30 Starmab Biologics (Suzhou) Co., Ltd Antigen-binding protein targeting pneumolysin and use thereof
CN117106077B (zh) * 2022-04-28 2024-07-16 珠海泰诺麦博制药股份有限公司 特异性结合金黄色葡萄球菌Hla毒素的全人源单克隆抗体
CN115894674B (zh) * 2022-12-20 2023-07-25 厦门润康源生物科技有限公司 一种用于检测冠状病毒的抗体及制备方法和应用
CN116789814B (zh) * 2023-06-27 2024-03-29 重庆原伦生物科技有限公司 一种特异性结合金黄色葡萄球菌α-溶血素的抗体及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
GB8426463D0 (en) 1984-10-19 1984-11-28 Technology Licence Co Ltd Monoclonal antibodies
CA2373221A1 (en) 1999-05-03 2000-11-30 Yashwant M. Deo Human antibodies to staphylococcus aureus
US6573096B1 (en) 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US7411046B2 (en) 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
WO2007081751A2 (en) 2006-01-05 2007-07-19 The Johns Hopkins University Compositions and methods for the treatment of cancer
US7420041B2 (en) 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
CN102585002A (zh) 2006-06-02 2012-07-18 瑞泽恩制药公司 人il-6受体的高亲和力抗体
US20180221466A9 (en) 2006-06-12 2018-08-09 Glaxosmithkline Biologicals S.A. Use of alpha-toxin for treating and preventing staphylococcus infections
US20090053235A1 (en) 2006-06-12 2009-02-26 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
KR20100072228A (ko) 2007-08-31 2010-06-30 유니버시티 오브 시카고 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
PL2644192T3 (pl) 2007-09-28 2017-09-29 Pfizer Inc. Ukierunkowanie na komórki nowotworowe z zastosowaniem nanocząstek
JP2011519974A (ja) 2008-05-12 2011-07-14 ストロックス バイオファーマスーティカルズ，エルエルシー 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）に特異的な抗体製剤
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
EP3916011A1 (en) 2009-06-26 2021-12-01 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
EP2284193A1 (en) * 2009-08-10 2011-02-16 Kenta Biotech AG Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation
CA2810030A1 (en) 2010-09-02 2012-03-08 Excelimmune, Inc. Staphylococcus aureus specific human recombinant polyclonal antibodies and uses thereof
RS58190B2 (sr) * 2011-02-08 2021-08-31 Medimmune Llc Antitela koja specifično vezuju staphylococcus aureus alfa toksin i postupci njihove primene
WO2013013323A1 (en) 2011-07-28 2013-01-31 Cangene Corporation Staphlococcus aureus alpha-hemolysin antibodies
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
CA2870223A1 (en) 2012-04-17 2013-10-24 Arsanis Biosciences Gmbh Cross-reactive staphylococcus aureus antibody
JP6506172B2 (ja) 2012-11-06 2019-04-24 メディミューン，エルエルシー 黄色ブドウ球菌（Ｓ．ａｕｒｅｕｓ）関連性疾患を治療する方法
BR112016008275A2 (pt) * 2013-10-17 2017-10-03 Arsanis Biosciences Gmbh Anticorpo com reatividade cruzada ao staphylococcus aureus, preparações farmacêuticas ou para diagnóstico compreendendo o anticorpo, anticorpo para uso médico e para diagnóstico, um ácido nucleico isolado que codifica o anticorpo, plasmideo ou cassete de expressao, e célula hospedeira compreendendo tal plasmideo ou cassete de expressao, método para produzir o anticorpo usando tal célula hospedeira, método para produzir variantes de anticorpos, um cristal formado por um monômero da hla ou lukd com dito anticorpo, um paratopo isolado do anticorpo, o epítopo isolado e uma molécula de ligação ligando especificamente ao dito epítopo, um método de triagem para identificar um ligante que se liga ao dito epítopo, um imunógeno compreendendo dito epítopo, e dito imunógeno usado para induzir uma resposta imune protetora
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
TWI702229B (zh) * 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
EP3283514A1 (en) 2015-04-17 2018-02-21 ARSANIS Biosciences GmbH Anti-staphylococcus aureus antibody combination preparation
TWI781130B (zh) 2017-01-03 2022-10-21 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體

Also Published As

Publication number Publication date
TW201837054A (zh) 2018-10-16
US10463748B2 (en) 2019-11-05
TW202311284A (zh) 2023-03-16
US20210162059A1 (en) 2021-06-03
JP2020504759A (ja) 2020-02-13
KR20190101435A (ko) 2019-08-30
US10940211B2 (en) 2021-03-09
BR112019013375A2 (pt) 2020-02-11
MA47202A (fr) 2019-11-13
CA3048989A1 (en) 2018-07-12
IL267600A (en) 2019-08-29
WO2018128973A1 (en) 2018-07-12
CL2019001836A1 (es) 2019-10-04
CO2019006902A2 (es) 2019-07-31
CN110167960B (zh) 2023-01-13
PH12019501425A1 (en) 2020-06-15
EA201991643A1 (ru) 2020-01-20
TWI781130B (zh) 2022-10-21
US11571482B2 (en) 2023-02-07
US20180214569A1 (en) 2018-08-02
CN110167960A (zh) 2019-08-23
EP3565835A1 (en) 2019-11-13
AU2018206531A1 (en) 2019-07-25
MX2019007784A (es) 2019-09-06
JP2023011710A (ja) 2023-01-24
US20200016275A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
AR110719A1 (es) Anticuerpos humanos a la toxina hemolisina a de s. aureus
AR110017A1 (es) Anticuerpos de pd-1 y usos de estos
ES2564252T3 (es) Anticuerpos anti-péptido beta-amiloide N3pGlu y usos de los mismos
AR110203A1 (es) Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
MX2019007848A (es) Anticuerpos anti-pd-1 y usos de los mismos.
CL2018001177A1 (es) Anticuerpos vinculados especificamente a pd-1 y sus usos.
AR126019A1 (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
PE20212088A1 (es) Anticuerpos anti-tau y uso de los mismos
PE20181921A1 (es) NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS
PE20210132A1 (es) Anticuerpos anti-cd3 y usos de estos
PE20210180A1 (es) Anticuerpos anti-cd33, anticuerpos biespecificos anti-cd33/anti-cd3 y usos de estos
PE20200011A1 (es) ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
AR052959A1 (es) Anticuerpos anti- ccr5 y usos de los mismos
CU24636B1 (es) Anticuerpos que reconocen tau en los residuos 257-271 o 320-334 de la seq id no: 1
CO6230999A2 (es) Anticuerpo anti-esclerostina
AR104906A1 (es) Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos
AR103713A1 (es) Anticuerpos contra tau y sus usos
AR096601A1 (es) Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
HRP20161587T1 (hr) Protutijela protiv bmp-6
AR098663A1 (es) Anticuerpos multifuncionales que se unen a egfr y met
AR110967A1 (es) Anticuerpos miméticos fgf21 y su uso
RU2017137496A (ru) Средство для лечения множественной миеломы (ММ)
AR105978A1 (es) Moléculas de unión a linfopoyetina estromal tímica (tslp) y métodos de uso de las moléculas
AR123480A1 (es) Moléculas de unión terapéuticas